14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KTTA vs ANRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (45.8/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 3–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus ANRO at $25.37 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: ANRO earns the overall head-to-head edge with a stronger Unified Composite Score (45.8/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.86β · 91% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KTTA vs ANRO. Trailing 12-month operating profitability (KTTA 0.0% vs ANRO 0.0%) and valuation multiples (KTTA N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KTTA vs ANRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (45.8/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 3–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus ANRO at $25.37 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ANRO earns the overall head-to-head edge with a stronger Unified Composite Score (45.8/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.86β · 91% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KTTA generates $486,559 in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.
KTTA screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ANRO (-46.7% ROE) capital efficiency.
In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ANRO carries 80.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 20.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.86β · 91% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.